The Cost of Being Heard
As the sales force arms race continues, with a nearly 50% industry-wide increase over the last three years, the cost of being heard has dramatically increased. Statitistics for selected drugs from top therapeutic categories reflect the pressure on companies to put more sales reps into the field.
You may also be interested in...
The decision limits US FDA discretion in determining how to regulate products that seem to meet both drug and device standards.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.